Shrinks In Sneakers

Tag: opioid pandemic

The Twin Epidemic: Rising Co-Prescriptions of Opioids and Stimulants in the U.S.
A recent 10-year longitudinal cohort study has unveiled concerning trends in the co-prescription of opioids and stimulants, shedding light on the escalating “twin epidemic” in the United States.

Key Findings:
- Prevalence of Co-Prescription: Approximately 5.5% of patients received both opioid and stimulant prescriptions during the study period.
- Increased Opioid Dosage: Patients co-prescribed stimulants were more likely to escalate their opioid doses over time, with the highest doses observed in the South and West regions.
- Associated Conditions: Common diagnoses among these patients included depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), and chronic pain
Implications:

The concurrent use of opioids and stimulants poses significant risks, including increased chances of overdose, cardiovascular events, and mental health complications. This study emphasizes the need for healthcare providers to carefully consider the implications of co-prescribing these medications and to monitor patients closely.

Call to Action:

It’s crucial to raise awareness about this emerging twin epidemic. Healthcare professionals, policymakers, and patients must collaborate to develop strategies that mitigate risks associated with co-prescriptions and ensure safer prescribing practices.
Share this:
X
Facebook
LinkedIn
Reddit
WhatsApp
Email
Like this:
Like Loading…
March 6, 2025
Buprenorphine vs. Methadone: The Battle for Opioid Use Disorder Treatment Supremacy
A recent study in JAMA compared the effectiveness of buprenorphine/naloxone versus methadone for opioid use disorder (OUD), focusing on treatment retention and mortality outcomes. The findings highlight important differences in these two mainstay treatments:
1. Treatment Retention: Methadone demonstrated significantly higher retention rates compared to buprenorphine/naloxone. Retention is a critical metric, as staying in treatment reduces the risk of relapse and overdose. In flexible-dose studies, buprenorphine/naloxone patients were 37–40% more likely to discontinue treatment than methadone recipients. This aligns with its pharmacological profile, as methadone provides more consistent suppression of withdrawal symptoms.
2. Mortality Rates: There were no significant differences in mortality risks between the two treatments, indicating both are comparably safe when provided in a supervised setting.
3. Dosing Implications: Higher doses of buprenorphine (≥16 mg/day) were associated with better retention and reduced emergency care visits, suggesting dose adequacy is vital in achieving optimal outcomes. However, underdosing or rigid dosing protocols may limit buprenorphine’s effectiveness in real-world settings.
4. Practical Considerations: Methadone requires daily visits to specialized clinics, which can be a barrier to care for some patients. In contrast, buprenorphine/naloxone can often be prescribed in primary care settings, improving accessibility.
The choice between methadone and buprenorphine/naloxone should be individualized, considering patient preferences, clinical circumstances, and potential barriers to adherence. These findings underscore the need for flexible treatment options tailored to the patient population.
Share this:
X
Facebook
LinkedIn
Reddit
WhatsApp
Email
Like this:
Like Loading…
December 7, 2024
Buprenorphine and Psychosis: Unraveling the Risks of Abrupt Discontinuation
This post is inspired by a real case from my practice involving a patient with no significant past psychiatric history but a strong history of substance use, including opioids and cocaine. The patient had been on buprenorphine maintenance therapy for several decades, providing stability in their recovery. However, following an abrupt discontinuation of buprenorphine, the patient developed acute psychotic symptoms. This case highlights an uncommon but important phenomenon clinicians should be aware of when managing buprenorphine discontinuation, especially in individuals with a history of substance use.

Emerging evidence suggests that abrupt discontinuation of buprenorphine may induce psychosis in some individuals, though this appears to be a relatively uncommon occurrence.

Documented Cases
- New-onset psychotic symptoms have been reported after sudden cessation of buprenorphine in patients with no prior psychosis.
- Common symptoms include auditory hallucinations, paranoid ideation, and delusions of reference.
- Psychotic symptoms typically emerge within days to weeks after discontinuation.
Potential Mechanisms
1. Loss of buprenorphine’s antipsychotic effects through kappa-opioid receptor antagonism.
2. Interaction between neurobiological vulnerabilities and the stress of withdrawal.
3. Possible unmasking of latent psychotic disorders.
Risk Factors
- History of substance use.
- Early adverse life events.
- Underlying psychiatric conditions (e.g., bipolar disorder).
Outcomes and Management
- Symptoms may resolve in weeks to months, though some cases persist longer.
- Reintroduction of buprenorphine has led to symptom remission in some cases, suggesting a causal relationship.
- Gradual tapering of buprenorphine might mitigate this risk, though more research is needed.
Clinical Implications

Clinicians should remain vigilant when discontinuing buprenorphine, especially in individuals with risk factors for psychosis. A gradual tapering strategy is recommended to reduce potential risks, though further studies are necessary to guide best practices.

Understanding this phenomenon highlights the importance of individualized care when managing buprenorphine discontinuation in vulnerable populations.
Share this:
X
Facebook
LinkedIn
Reddit
WhatsApp
Email
Like this:
Like Loading…
December 2, 2024
Abrupt Discontinuation of Buprenorphine and Risk of Psychosis: Clinical Considerations
This post is inspired by a real case from my practice involving a patient with no significant past psychiatric history but a strong history of substance use, including opioids and cocaine. The patient had been on buprenorphine maintenance therapy for several decades, providing stability in their recovery. However, following an abrupt discontinuation of buprenorphine, the patient developed acute psychotic symptoms. This case highlights an uncommon but important phenomenon clinicians should be aware of when managing buprenorphine discontinuation, especially in individuals with a history of substance use.

Emerging evidence suggests that abrupt discontinuation of buprenorphine may induce psychosis in some individuals, though this appears to be a relatively uncommon occurrence. Here are the key findings:

Documented Cases
- New-onset psychotic symptoms have been reported after sudden cessation of buprenorphine in patients with no prior psychosis.
- Common symptoms include auditory hallucinations, paranoid ideation, and delusions of reference.
- Psychotic symptoms typically emerge within days to weeks after discontinuation.
Potential Mechanisms
1. Loss of buprenorphine’s antipsychotic effects through kappa-opioid receptor antagonism.
2. Interaction between neurobiological vulnerabilities and the stress of withdrawal.
3. Possible unmasking of latent psychotic disorders.
Risk Factors
- History of substance use.
- Early adverse life events.
- Underlying psychiatric conditions (e.g., bipolar disorder).
Outcomes and Management
- Symptoms may resolve in weeks to months, though some cases persist longer.
- Reintroduction of buprenorphine has led to symptom remission in some cases, suggesting a causal relationship.
- Gradual tapering of buprenorphine might mitigate this risk, though more research is needed.
Clinical Implications

Clinicians should remain vigilant when discontinuing buprenorphine, especially in individuals with risk factors for psychosis. A gradual tapering strategy is recommended to reduce potential risks, though further studies are necessary to guide best practices.

Understanding this phenomenon highlights the importance of individualized care when managing buprenorphine discontinuation in vulnerable populations.
Share this:
X
Facebook
LinkedIn
Reddit
WhatsApp
Email
Like this:
Like Loading…
November 19, 2024
Locked Out: Why Most Inmates Are Denied Life-Saving Opioid Treatment
The JAMA Network Open article titled “Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails” investigates the availability of medications for opioid use disorder (MOUD) in U.S. jails, such as methadone, buprenorphine, and naltrexone. It highlights that MOUD, which is a critical component in treating opioid use disorder (OUD), is underutilized in correctional facilities, despite its effectiveness in reducing overdose rates, withdrawal symptoms, and recidivism.

Key factors influencing MOUD availability in jails include jail size, regional location, the political landscape, and resources available in the facility. Jails in larger urban areas or those in states with Medicaid expansion are more likely to provide MOUD. Barriers such as stigma, lack of funding, and inadequate healthcare infrastructure also limit access to these medications.

The study emphasizes the importance of expanding access to MOUD in jails to address the opioid epidemic and improve public health outcomes for incarcerated populations as only 44% of jails offer MOUD in the current system.
Share this:
X
Facebook
LinkedIn
Reddit
WhatsApp
Email
Like this:
Like Loading…
September 25, 2024
Be Cautious with Gabapentin in Patients on MAT for Opioid Use Disorder
In my practice, I frequently see patients on Medication-Assisted Treatment (MAT) for opioid use disorder, whether it’s Suboxone or methadone, also being prescribed high-dose gabapentin—often without a clear indication for its use. This raises some serious red flags. ⚠️

While gabapentin can be useful in certain situations, we know there’s an increased risk of overdose when it’s combined with opioids, especially in those with a history of opioid use disorder. Gabapentin can suppress the central nervous system, making it more dangerous in combination with other sedating medications.

If there’s no solid reason for the prescription, it’s best to steer clear. Always prioritize safety and question if gabapentin is truly necessary in these cases. Let’s keep patient care and harm reduction at the forefront.

💡 Key takeaway: If there’s no clear indication, think twice before prescribing gabapentin to someone on MAT. Their safety depends on it.
Share this:
X
Facebook
LinkedIn
Reddit
WhatsApp
Email
Like this:
Like Loading…
September 24, 2024
Want to Live Longer with a Serious Mental Health Condition? Say No to Alcohol, Drugs, and Smoking!
The article “Major Psychiatric Disorders, Substance Use Behaviors, and Longevity” explores the complex relationships between psychiatric disorders, substance use, and life expectancy. The authors examine how conditions like schizophrenia, bipolar disorder, and major depression affect longevity, often leading to reduced lifespans. This is largely due to increased risk factors, such as poor physical health, unhealthy lifestyles, and increased rates of suicide.

Substance use behaviors, including alcohol, tobacco, and drug use, often co-occur with psychiatric disorders, compounding the negative effects on longevity. The article emphasizes the need for better integration of mental health and substance use treatment into healthcare systems. It also advocates for targeted interventions to reduce mortality rates, improve the quality of life, and enhance access to comprehensive care for individuals with psychiatric disorders.

Link to the article: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2820199
Share this:
X
Facebook
LinkedIn
Reddit
WhatsApp
Email
Like this:
Like Loading…
September 21, 2024